"10.1371_journal.pone.0143073","plos one","2015-12-02T00:00:00Z","José Ángel Hernández; María Hernández-Sánchez; Ana Eugenia Rodríguez-Vicente; Vera Grossmann; Rosa Collado; Cecilia Heras; Anna Puiggros; Ana África Martín; Noemí Puig; Rocío Benito; Cristina Robledo; Julio Delgado; Teresa González; José Antonio Queizán; Josefina Galende; Ignacio de la Fuente; Guillermo Martín-Núñez; José María Alonso; Pau Abrisqueta; Elisa Luño; Isabel Marugán; Isabel González-Gascón; Francesc Bosch; Alexander Kohlmann; Marcos González; Blanca Espinet; Jesús María Hernández-Rivas; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC)","Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain; IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain; MLL Munich, Germany; Hematology Department, Hospital General, Valencia, Spain; Pathology Department, Hospital del Mar, Barcelona, Spain; Hematology Department, Hospital Universitario, Salamanca, Spain; Hematology Department, Hospital Clinic i Provincial, Barcelona, Spain; Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain; Hematology Department, Hospital General, Segovia, Spain; Hematology Department, Hospital del Bierzo, Ponferrada, León, Spain; Hematology Department, Hospital Universitario Río Hortega, Valladolid, Spain; Hematology Department, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain; Hematology Department, Hospital Río Carrión, Palencia, Spain; Hematology Department, Hospital Vall dHebron, Barcelona, Spain; Hematology Department, Hospital Central de Asturias, Oviedo, Spain; Hematology Department, Hospital Clínico, Valencia, Spain; AstraZeneca, Personalized Healthcare and Biomarkers, Innovative Medicines, Macclesfield, United Kingdom; Department of Medicine, Universidad de Salamanca, Spain","Conceived and designed the experiments: JAH MHS AERV JMHR. Performed the experiments: MHS AERV CR RB. Analyzed the data: JAH MHS AERV CR RB. Contributed reagents/materials/analysis tools: VG AK RC CH AP AAM NP JD TG JAQ JG IF GMN JMA PA EL IM IG MG. Wrote the paper: JAH MHS AERV CR RB VG FB BE MG JMHR.","The authors have declared that no competing interests exist. Oligonucleotide primer plates for amplicon deep-sequencing were provided by Roche Diagnostics, Penzberg, Germany, as part of the IRON-II study. VG and AK were employed by MLL Munich Leukemia Laboratory and AK is employed by AstraZeneca. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","12","José Ángel Hernández","JÁH",28,FALSE,4,4,5,10,FALSE,FALSE,TRUE,2,"1;8",TRUE
